CPH – Creso Pharma Ltd


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Creso Pharma Limited is an Australia-based cannabis company. The Company is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product pipeline includes cannaQIX50, cannaQIX10, cannaQIX25 and Medicinal CBD oil and others. In addition, the Company cultivates and harvests cannabis plants through its wholly owned subsidiary, Mernova Medicinal Inc. (Mernova) and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc. (Halucenex), it also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan